Sanofi Recalls Zantac Amid Concerns of NDMA Contamination




BRIDGEWATER, N.J. — Drug maker Sanofi has announced that it is voluntarily recalling its over-the-counter heartburn drug Zantac (ranitidine) amid concerns that it was contaminated by a probable human carcinogen known as N-nitrosodimethylamine (NDMA).

In an Oct. 18 press release, the company said it “is working with health authorities to determine the level and extent of the recall.”

“Active ingredients used in Sanofi's ranitidine products outside of the U.S. and Canada are sourced from different suppliers,” the press release says. “Sanofi is committed to transparency and will continue to communicate results with health authorities from the ongoing testing, and work …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Midwest Asbestos Litigation

December 02, 2020 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS